Gyre Therapeutics (GYRE) Form 3 Initial statement of insider ownership

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

GNI Group Ltd.

(Last) (First) (Middle)

NIHONBASHI-HONCHO YS BLDG 3F

2-2-2 NIHONBASHI-HONCHO, CHUO-KU

(Street)

TOKYO M0 103-0023

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/27/2023

3. Issuer Name and Ticker or Trading Symbol
CATALYST BIOSCIENCES, INC. [ CBIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,266,521	I	See footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series X Convertible Preferred Stock	(2)	(3)	Common Stock	123,400,000	(2)	I	See footnote(1)

1. Name and Address of Reporting Person^*

GNI Group Ltd.

(Last) (First) (Middle)

NIHONBASHI-HONCHO YS BLDG 3F

2-2-2 NIHONBASHI-HONCHO, CHUO-KU

(Street)

TOKYO M0 103-0023

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

GNI USA, Inc.

(Last) (First) (Middle)

12730 HIGH BLUFF DRIVE

SUITE 250

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

Explanation of Responses:

1. These securities are held by GNI USA, Inc., a Delaware corporation ("GNI USA"), which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.

2. Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).

3. The Preferred Stock has no expiration date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.	10/27/2023
	/s/ Branden Berns, as attorney-in-fact for GNI USA, Inc.	10/27/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.